文献速递妇科肿瘤

铂敏感复发卵巢癌二次减瘤术联合化疗对比单纯化疗的III期随机试验

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-03-08

SOC-1研究在中国四家中心纳入357例铂敏感复发上皮性卵巢癌患者,按1:1随机分为二次减瘤术联合化疗组(182例)或单纯化疗组(175例)。

要点

  • 二次减瘤术联合化疗显著延长铂敏感复发卵巢癌的无进展生存期。
  • 总生存中期分析未显示显著差异,需等待成熟数据。
  • 手术组30天3-4级手术并发症发生率为5%,无治疗相关死亡。

核心结论

  • 在铂敏感复发卵巢癌患者中,二次减瘤术联合化疗较单纯化疗显著延长无进展生存期。

研究设计与样本

  • 多中心、开放标签、随机对照III期试验(SOC-1),在中国四家中心开展。
  • 2012年7月19日至2019年6月3日共纳入357例患者,随机分为手术组182例和无手术组175例(ITT人群)。
  • eligible患者为铂敏感复发上皮性卵巢癌,铂 free interval≥6个月,经iMODEL评分和PET-CT评估为潜在可切除。
  • 按1:1随机分配,分层因素包括研究中心、iMODEL评分、初次手术残余病灶和SUNNY试验入组情况。
  • 主要终点为无进展生存期和总生存期,按ITT分析。

主要发现

  • 无手术组中11例(6%)在二线治疗中接受二次减瘤术,48例(37%)疾病进展后交叉手术。
  • 安全性人群中,手术组172例中9例(5%)在30天出现3-4级手术并发症;化疗期间最常见的3-4级不良事件为中性粒细胞减少(手术组29/166例[17%] vs 无手术组19/156例[12%])、白细胞减少(14例[8%] vs 8例[5%])和贫血(10例[6%] vs 9例[6%])。

关键数值与推荐

  • 化疗方案为静脉紫杉醇175 mg/m2或docetaxel 75 mg/m2联合卡铂AUC 5 mg/mL per min,每3周一次,共6周期。

临床怎么用

  • 对铂敏感复发卵巢癌患者,可考虑在专科中心行二次减瘤术联合化疗以延长无进展生存期。
  • 应与患者讨论二次减瘤术的选项,并告知总生存获益尚未明确。

局限性

  • 总生存数据为中期分析,尚未成熟。
  • 无手术组存在交叉手术,可能影响总生存分析。
  • 研究仅限于中国四家 primarily academic centres,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefits of secondary cytoreduction for platinum-sensitive relapsed ovarian cancer are still widely debated. We aimed to assess the efficacy of secondary cytoreduction plus chemotherapy versus chemotherapy alone in this patient population. METHODS: This multicentre, open-label, randomised, controlled, phase 3 trial (SOC-1), was done in four primarily academic centres in China (two in Shanghai, one in Hangzhou, and one in Guangzhou). Eligible patients were women aged 18 years and older with platinum-sensitive relapsed epithelial ovarian cancer with a platinum-free interval of at least 6 months after the end of first-line platinum-based chemotherapy and were predicted to have potentially resectable disease according to the international model (iMODEL) score and PET-CT imaging. iMODEL score was calculated using six variables: International Federation of Gynecology and Obstetrics stage, residual disease after primary surgery, platinum-free interval, Eastern Cooperative Oncology Group performance status, serum level of cancer antigen 125 at recurrence, and presence of ascites at recurrence. An iMODEL score of 4·7 or lower predicted a potentially complete resection. As per a protocol amendment, patients with an iMODEL score of more than 4·7 could only be included if the serum level of cancer antigen 125 was more than 105 U/mL, but the principal investigators assessed the disease to be resectable by PET-CT. Eligible participants were randomly assigned (1:1) via a permuted block design (block size of six) and stratified by study centre, iMODEL score, residual disease at primary surgery, and enrolment in the Shanghai Gynecologic Oncology Group SUNNY trial, to undergo secondary cytoreductive surgery followed by intravenous chemotherapy (six 3-weekly cycles of intravenous paclitaxel [175 mg/m2] or docetaxel [75 mg/m2] combined with intravenous carboplatin [area under the curve of 5 mg/mL per min]; surgery group) or intravenous chemotherapy alone (no surgery group). Primary endpoints were progression-free survival and overall survival, analysed in all participants randomly assigned to treatment, regardless of treatment received (intention-to-treat [ITT] population). Here, we report the final analysis of progression-free survival and the prespecified interim analysis of overall survival. Safety was assessed in all participants who received their assigned treatment and had available adverse event data. This study is registered with ClinicalTrials.gov, NCT01611766, and is ongoing but closed to accrual. FINDINGS: Between July 19, 2012, and June 3, 2019, 357 patients were recruited and randomly assigned to the surgery group (182) or the no surgery group (175; ITT population). Median follow-up was 36·0 months (IQR 18·1-58·3). In the no surgery group, 11 (6%) of 175 participants had secondary cytoreduction during second-line therapy while 48 (37%) of 130 participants who had disease progression crossed-over and had surgery at a subsequent recurrence. Median progression-free survival was 17·4 months (95% CI 15·0-19·8) in the surgery group and 11·9 months (10·0-13·8) in the no surgery group (hazard ratio [HR] 0·58; 95% CI 0·45-0·74; p<0·0001). At the interim overall survival analysis, median overall survival was 58·1 months (95% CI not estimable to not estimable) in the surgery group and 53·9 months (42·2-65·5) in the no surgery group (HR 0·82, 95% CI 0·57-1·19). In the safety population, nine (5%) of 172 patients in the surgery group had grade 3-4 surgical morbidity at 30 days, and no patients in either group had died at 60 days after receiving assigned treatment. The most common grade 3-4 adverse events during chemotherapy were neutropenia (29 [17%] of 166 patients in the surgery group vs 19 [12%] of 156 patients in the no surgery group), leucopenia (14 [8%] vs eight [5%]), and anaemia (ten [6%] vs nine [6%]). Four serious adverse events occurred, all in the surgery group. No treatment-related deaths occurred in either group. INTERPRETATION: Secondary cytoreduction followed by chemotherapy was associated with significantly longer progression-free survival than was chemotherapy alone in patients with platinum-sensitive relapsed ovarian cancer, and patients should be counselled about the option of secondary cytoreduction in specialised centres. Long-term survival outcomes will be assessed using mature data on overall survival. FUNDING: Zhongshan Development Program. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021. PMID: 33705695. doi:10.1016/S1470-2045(21)00006-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。